ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Nov 30, 2014
Dividend Increases for the Week Ending November 28
Let's take a look at dividend increases for the week ending November 28.
Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.
Jun 9, 2014
The M&A Environment Remains Robust
Let’s take a look at a few deals that hit the wires recently – some proposed, some speculated.
Mar 21, 2014
Update: Digging Into the Valuentum Dividend Cushion
We explain our innovative, predictive, and forward-looking indicator that assesses the safety of a firm's future dividends. The Valuentum Dividend Cushion flashed a red flag for every firm that cut their dividend in our database.
Feb 28, 2014
Thank you…
We can’t begin to tell you how much we appreciate feedback.
Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space .
Dec 23, 2013
Three Reasons Why Dividend Growth Investors Are Quite Savvy
Let's examine today's dividend growth investor.
Nov 30, 2013
Dividend Increases for the Week Ending November 29
Let's take a look at dividend increases for the week ending November 29.
Oct 29, 2013
Pfizer’s and Merck’s 3Q Performance
Let’s take a look at fundamental performance of Pfizer and Merck during the third quarter.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.